Royalty Pharma

RPRX | NASDAQ

Price Alert Chart Builder DCF Calculator

$58.44

+$0.03 (+0.05%)

At close: Sep 21, 2026, 4:00 PM ET

$58.44

$0 (0.00%)

Pre-market: Sep 22, 2026, 7:37 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Dividends Profile

Market Data

Market Cap $25.9B

Enterprise Value $34.03B

Beta 0.43

Average Volume 3.4M

Shares Outstanding (Diluted) 556.9M

Shares Change YoY -0.96%

Institutional Ownership 82.84%

Exchange NASDAQ

ISIN GB00BMVP7Y09

Price Performance

Price Change 1M -4.7%

Price Change 3M 5.6%

Price Change 6M 24.3%

Price Change YTD 50.4%

Price Change 1Y 63.0%

Price Change 3Y 122.0%

Price Change 5Y 57.5%

1M CAGR (ann.) 3.4%

1Y CAGR (ann.) 66.7%

5Y CAGR (ann.) 11.3%

All-Time CAGR 6.7%

Valuation

PE Ratio 33.59

Forward PE 8.06

PEG Ratio 7.06

Forward PEG 3.31

PS Ratio 10.21

Forward PS 6.80

PB Ratio 2.65

P/FCF Ratio 6.93

P/Adj. FCF Ratio 7.32

P/OCF Ratio 8.74

EV/Sales 13.42

EV/EBIT 19.89

EV/EBITDA 19.85

EV/FCF 9.11

Earnings Yield 3.0%

FCF Yield 14.4%

Adj. FCF Yield 13.7%

Financial Health

Net Debt $8.12B

Total Debt $8.96B

Cash & Short-Term Investments $836.99M

Total Assets $19.82B

Current Ratio 1.29

Quick Ratio 1.29

Debt / Equity Ratio 1.31

Debt / EBITDA 5.23

Debt / FCF 2.40

OCF / Debt 0.42

Interest Coverage 4.38

Altman Z-Score 2.15

Piotroski F-Score 5

Margins & Profitability

Gross Profit Margin 89.4%

Operating Profit Margin 62.3%

EBITDA Margin 67.7%

Net Profit Margin 32.1%

FCF Margin 147.4%

Adj. FCF Margin 139.5%

SBC / Revenue 7.8%

SBC Impact (per share) -5.3%

Returns

Return on Assets 4.1%

Return on Equity 12.3%

Return on Invested Capital 9.0%

Return on Capital Employed 8.2%

Return on Tangible Assets 4.3%

Historical Growth (CAGR)

Revenue CAGR 3Y 2.4%

Revenue CAGR 5Y 2.5%

Revenue CAGR 10Y 3.7%

EPS CAGR 3Y 72.3%

EPS CAGR 5Y 6.8%

EPS CAGR 10Y 6.5%

FCF CAGR 3Y 10.8%

FCF CAGR 5Y 11.9%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 11

EPS Growth Next 3Y 44.1%

Revenue Growth Next 3Y 22.7%

Earnings Date Nov 3, 2026

EPS Estimate (next Q) $1.18

EPS Growth Est (next Q) 0.8%

Revenue Est (next Q) $877.37M

Revenue Growth Est (next Q) 44.0%

Fair Value Estimates

Graham Number $29.34

Graham Upside -49.8%

Lynch Fair Value $11.90

Lynch Upside -79.6%

Price Target $62.67

Price Target Upside 7.2%

Cash Flow

Operating Cash Flow $3.74B

Free Cash Flow $3.74B

Adj. Free Cash Flow $3.54B

FCF Per Share $6.69

OCF Per Share $6.69

OCF/S Ratio 117.4%

Income Statement

Revenue $2.54B

Gross Profit $2.27B

Operating Income $1.58B

EBITDA $1.71B

Net Income $815.31M

EPS (Diluted) $1.74

Revenue / Employee $25.36M

Profit / Employee $8.15M

Employees 100

Dividends

Annual Dividend $0.92

Dividend Yield 1.57%

Payout Ratio 53.2%

FCF Payout Ratio 13.5%

Adj. FCF Payout Ratio 14.2%

Dividend Growth (YoY) 6.3%

Pay Frequency Quarterly

Ex-Dividend Date Aug 13, 2026